Description: Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Home Page: spagonanomedical.se
Scheelevägen 22
Lund,
223 63
Sweden
Phone:
46 4 68 11 88
Officers
| Name | Title |
|---|---|
| Dr. Mats Hansen M.Sc., Ph.D. | Chief Exec. Officer |
| Ms. Hanna Olsson M.Sc. | Chief Financial Officer |
| Dr. Oskar Axelsson M.Sc., Ph.D. | VP, Head of Research & Chief Scientific Officer |
| Mr. Paul Hargreaves | Chief Devel. Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 4.6838 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.275 |
| Price-to-Sales TTM: | 9.4818 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |